Consonance Capital Management LP Krystal Biotech, Inc. Transaction History

Consonance Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$37.03 - $60.0 $24.2 Million - $39.3 Million	-654,586 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $15.8 Million - $29.6 Million	450,798 Added 221.21%	654,586 $28.3 Million
Q4 2019 Feb 14, 2020	SELL	$33.17 - $65.23 $673,417 - $1.32 Million	-20,302 Reduced 9.06%	203,788 $11.3 Million
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $1.46 Million - $2.15 Million	42,000 Added 23.07%	224,090 $7.78 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $4.95 Million - $7.5 Million	182,090 New	182,090 $7.33 Million

310

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.12B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.